Chemotherapy and/or radiotherapy after surgery for ovarian carcinosarcoma

Athavale, R.; Deane, Katherine

doi:10.1002/14651858.cd006246

Cited by 2 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Les é lé ments ayant conduit à la mise à jour de ce thè me, la straté gie de recherche bibliographique, les critè res de sé lection des é tudes, les ré sultats de la sé lection bibliographique pour chaque thè me traité , les critè res d'é valuation, l'analyse des donné es, la description des é tudes, les conclusions de la litté rature, le jugement argumenté des experts du groupe de travail, les modifications apporté es aux recommandations du document publié en 2003, le processus de relecture ainsi que la liste des contributeurs du projet sont pré senté s dans le rapport inté gral disponible sur le site internet des SOR à l'adresse suivante : www.sor-cancer.fr. [2][3][4]6,7,12,13,20,21,23,25,28,[31][32][33][34][35][36][37][39][40][41][42][43]46] Essais randomisé s de phase II [8,10,27] Sites internet EBM RPC 1 [11,14,15,29,38] Protocoles 2 [5,9,30,44] -Stades IA ou IB G3, cellules claires ou stades supé rieurs ou é gaux à IC : une chimiothé rapie intraveineuse à base de sels de platine comportant au moins trois cures doit ê tre ré alisé e.…”

Section: Standards Et Options (Voir Tableau 1)unclassified

“…5 -Chimiothé rapie intrapé ritoné ale (standard ou hyperthermique) dans le cadre de protocoles d'é valuation.…”

Section: Standardunclassified

“…5 Options issues de la RPC-SOR : SOR 2007 pour la prise en charge des patientes atteintes de tumeurs é pithé -liales malignes de l'ovaire -« Traitement chirurgical » -disponible en version inté grale sur le site internet des SOR à l'adresse suivante : www. sor-cancer.fr.…”

Section: Standardunclassified

See 2 more Smart Citations

Clinical Practice Guidelines: 2008 Update of Standards, Options: Recommendations for the management of patient with epithelial ovarian cancer — medical front-line treatment — (summary report)

et al. 2008

View full text Add to dashboard Cite

Recommandations pour la pratique clinique : Standards, Options : Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs é pithé liales malignes de l'ovaire. Traitement mé dical de premiè re ligne (rapport abré gé ) AuteursComité ré dacteur C. Lhommé , oncologue mé dical (coordinatrice), institut Gustave-Roussy, Tous les droits de reproduction, repré sentation, ainsi que de traduction sur ce texte appartiennent exclusivement à la FNCLCC, quel que soit le support utilisé . Ainsi, tout projet de reproduction ou de diffusion de ce texte, doit pré alablement faire l'objet d'une autorisation expresse de la FNCLCC.

show abstract

Section: Standards Et Options (Voir Tableau 1)unclassified

“…5 -Chimiothé rapie intrapé ritoné ale (standard ou hyperthermique) dans le cadre de protocoles d'é valuation.…”

Section: Standardunclassified

See 1 more Smart Citation

Clinical Practice Guidelines: 2008 Update of Standards, Options: Recommendations for the management of patient with epithelial ovarian cancer — medical front-line treatment — (summary report)

et al. 2008

View full text Add to dashboard Cite

show abstract

“…1,2 Despite the development of medical technology, surgery and chemotherapy are still the main approaches for prolonging the life of patients with ovarian cancer. 3,4 However, ovarian cancer cells usually exhibit resistance to chemotherapy and it is necessary to develop strategies to increase their sensitivity to chemotherapeutic drugs. 5,6 Cisplatin is a platinum-based cytotoxic agent that is commonly used for the treatment of various types of malignant cancers including ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

<p>miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer</p>

Yang¹,

Li²,

Luo³

2020

OTT

View full text Add to dashboard Cite

Background: Cisplatin is a commonly used drug for the treatment of various types of malignant cancers, including ovarian cancer. However, resistance to cisplatin is still a considerable obstacle to achieve a satisfactory therapeutic effect. The purpose of this study is to develop a strategy to sensitize ovarian cancer cells to cisplatin-induced cytotoxicity. Methods: miR-34c levels in ovarian cancer tissues and cell lines were tested by qRT-PCR analysis. In vitro assays, the effect of miR-34c on cisplatin was evaluated by using MTT. Expression of MET and phosphorylation of PI3K and AKT were tested by Western blot assays. Conjugation with Bad and Bcl-xl was evaluated through immunoprecipitation. Flow cytometry analysis was performed to measure the apoptotic rate of ovarian cancer cells. Results: Downregulation of miR-34c was observed in ovarian cancer tissues and cell lines. However, miR-34c overexpression was found to sensitize ovarian cancer cells to cisplatin treatment in vitro and in vivo. Mechanically, we found that miR-34c targeted the MET gene, thereby inhibiting the phosphorylation of PI3K and AKT to activate Bad. As a result, miR-34c reduced resistance of ovarian cancer cells to cisplatin-induced apoptosis. Conclusion: miR-34c/MET axis promotes cisplatin-induced cytotoxicity against ovarian cancer by targeting the MET/PI3K/AKT/Bad pathway.

show abstract

Chemotherapy and/or radiotherapy after surgery for ovarian carcinosarcoma

Cited by 2 publications

References 12 publications

Clinical Practice Guidelines: 2008 Update of Standards, Options: Recommendations for the management of patient with epithelial ovarian cancer — medical front-line treatment — (summary report)

Clinical Practice Guidelines: 2008 Update of Standards, Options: Recommendations for the management of patient with epithelial ovarian cancer — medical front-line treatment — (summary report)

<p>miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer</p>

Contact Info

Product

Resources

About